Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL–negative MPN in blast phase

There is a limited understanding of the clinical and molecular factors associated with outcomes of hematopoietic cell transplantation (HCT) in patients with BCR-ABL–negative myeloproliferative neoplasms in blast phase (MPN-BP). Using the Center for International Blood and Marrow Transplant Research...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Adv
Autors principals: Gupta, Vikas, Kennedy, James A., Capo-Chichi, Jose-Mario, Kim, Soyoung, Hu, Zhen-Huan, Alyea, Edwin P., Popat, Uday R., Sobecks, Ronald M., Scott, Bart L., Gerds, Aaron T., Salit, Rachel B., Deeg, H. Joachim, Nakamura, Ryotara, Saber, Wael
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2020
Matèries:
Myeloid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7656913/
https://ncbi.nlm.nih.gov/pubmed/33170935
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002727
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars